Risankizumab granted Orphan Drug Designation by FDA

Risankizumab is being assessed for the treatment of immunological disorders such as Crohn’s disease.
Risankizumab is being assessed for the treatment of immunological disorders such as Crohn’s disease. | File photo
AbbVie's risankizumab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the investigational treatment of pediatric patients who have Crohn’s disease.
"AbbVie is committed to providing innovative treatment options to patients, particularly in areas with unmet medical needs such as Crohn's disease in children – a disease that may impact physical and social development," AbbVie Executive Vice President of Research Dr. Michael Severino said. "This designation reinforces the need for additional treatment options for young people living with this sometimes debilitating disease. Our expertise in immunology provides a unique perspective and we look forward to continuing to evaluate risankizumab as a potential new therapy for patients."
Risankizumab is being assessed for the treatment of immunological disorders such as Crohn’s disease, psoriasis, psoriatic arthritis and asthma. Risankizumab is the results of a partnership between Boehringer Ingelheim and AbbVie, with AbbVie handling the development and commercialization of the drug on a worldwide scale.
The drug has yet to be approved by regulatory authorities.
Want to get notified whenever we write about AbbVie ?
Next time we write about AbbVie, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

AbbVie 1 N Waukegan Rd Lake Bluff, IL - 60044